ArticleJournal of inflammation (London, England)2026
Quercetin-loaded silicon dioxide-graphene nanoparticles promotes M2 macrophage reprogramming in mycoplasma-induced pneumonia.
Article in Journal of inflammation (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveTo develop and evaluate a quercetin-loaded silicon dioxide-graphene nanocomposite (Que@SiO₂-GNPs) for targeted macrophage modulation and epithelial protection in a Mycoplasma-induced pneumonia model.
methodsQue@SiO₂-GNPs were synthesized via graphene oxide dispersion, sol-gel silica coating, and quercetin adsorption. Physicochemical properties were characterized by XPS, XRD, and FTIR. The therapeutic efficacy was evaluated in MP-infected rat models via histopathology, ELISA, flow cytometry, immunostaining, and Western blot. Cellular uptake, polarization, and functional assays were performed in primary AMs and BEAS-2B epithelial cells.
resultsQue@SiO₂-GNPs exhibited successful surface modification and quercetin incorporation with stable physicochemical properties. In vivo imaging demonstrated pulmonary targeting and favorable biocompatibility. In MP-infected rats, Que@SiO₂-GNPs significantly reduced pro-inflammatory cytokines (TNF-α, IL-6, IL-1β), alleviated lung injury, and promoted tissue repair. Mechanistically, the nanocomposites downregulated iNOS and CD86 while enhancing CD206 expression in AMs, indicating M2 polarization. Conditioned AMs improved epithelial proliferation, reduced oxidative stress and apoptosis, and upregulated SPLUNC1 expression. These outcomes were validated by EdU, ROS, Annexin V/PI, LDH assays, and protein expression analyses.
conclusionsQue@SiO₂-GNPs effectively reprogrammed macrophage phenotypes toward M2, suppressed inflammation, and conferred epithelial protection in Mycoplasma-induced pneumonia. This nanoplatform represents a promising immunomodulatory strategy for pulmonary infectious diseases. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.